Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
Karyopharm Therapeutics 2024年第一季度公認會計准則每股收益美元（0.32）超過預期（0.33）美元，銷售額3312.6萬美元低於預期的344.73億美元
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $33.126 million which missed the analyst consensus estimate of $34.473 million by 3.91 percent. This is a 14.40 percent decrease over sales of $38.698 million the same period last year.
Karyopharm Therapeutics（納斯達克股票代碼：KPTI）公佈的季度虧損爲每股0.32美元，比分析師普遍預期的0.33美元（0.33美元）高出3.03％。這比去年同期每股虧損0.30美元（0.30美元）下降了6.67％。該公司公佈的季度銷售額爲3312.6萬美元，比分析師普遍預期的347.3萬美元低3.91％。這比去年同期的3,869.8萬美元的銷售額下降了14.40％。